From One Terminator to Twelve Years of Building DNA

Leading the technical commercial team that bridges customers with Product and R&D. Defining pricing and promotional strategies for BioXp reagents while triaging opportunities across the BioXp, Biofoundry Services, and SOLA product lines.

• Serve as front-line voice of the customer, translating field insights into product requirements for R&D and Product Management.
• Define pricing and promotional strategies for BioXp reagent consumables, balancing margin targets with customer adoption.
• Triage inbound opportunities across BioXp, Biofoundry Services, and SOLA platforms, routing to the right solution for each customer need.
• Coach and develop a team of field application scientists delivering technical sales support across the product portfolio.

Pivoted from R&D into corporate strategy, building the business case for SOLA enzymatic DNA synthesis technology. Identified and engaged strategic partners, developed financial models for licensing negotiations, and validated product specifications through custom NGS pipelines.

• Built cost and throughput models that articulated SOLA's value proposition, directly supporting licensing negotiations and strategic partnership discussions.
• Proactively engaged potential partners through industry networking and targeted outreach, expanding the partnership pipeline for enzymatic DNA synthesis technology.
• Collaborated with stakeholders to identify and qualify automation partners, enhancing workflow scalability and commercial viability.
• Developed custom NGS bioinformatics pipelines to validate synthesis fidelity specifications — translating raw sequencing data into product claims.

Directed Biofoundry Services, the company's custom DNA synthesis arm. Launched new product lines, transformed manufacturing quality, and served as the technical bridge between customers, sales, and production.

• Launched DNA Library Services product line from concept to revenue — identified the market opportunity, built the offering, and aligned R&D, manufacturing, and commercial teams to ship on aggressive timelines.
• Improved manufacturing first-pass rate from 54% to 100% through systematic process optimization and quality engineering.
• Reduced COGS 15% on a critical synthesis reagent, improving unit economics across the product portfolio.
• Served as primary technical liaison in sales engagements, consulting on DNA library design and directly influencing six-figure purchasing decisions.
• Managed technology transfer of DNA synthesis and plasmid verification workflows to GMP contract manufacturers, ensuring scalability and regulatory compliance.
• Proved that error-correction works on degenerate-base DNA libraries without collapsing sequence diversity — a technical breakthrough that unlocked a new product category.

Project Manager and scientific SME for the launch of the first GMP manufacturing facility producing synthetic DNA for personalized immunotherapy — a high-stakes engagement where technical precision had direct patient impact.

• Developed the Synthesis Optimization Tool (SOT) for codon optimization with minimized synthesis complexity — this tool won SGI-DNA its first GMP customer and enabled their IND submission.
• Led the team through engineering runs required for the customer's successful IND submission to the FDA.
• Updated and validated the sequence complexity engine, improving BioXp build prediction accuracy from ~80% to over 95%.

Founding team member of SGI-DNA, spun out of Craig Venter's Synthetic Genomics. Built the DNA synthesis and sequencing services operation from the ground up — the revenue engine that funded the company's early growth.

• Built the DNA synthesis services operation from scratch, growing it to $8M+ in annual revenue.
• Provided technical sales support, advising customers on sequence design, synthesis feasibility, and workflow optimization.
• Managed complex custom orders across synthesis, cloning, and sequencing services.
• Improved on-time shipment rates by 20%+ during a stint as interim VP of Operations, transitioning production from project-based to workstation-based manufacturing.